Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality

被引:12
作者
Baalbergen, Astrid
Ewing-Graham, Patricia C.
Eijkemans, Marinus J.
Helmerhorst, Theo J. M.
机构
[1] Reinier De Graaf Grp, Dept Obstet & Gynecol, NL-2600 GA Delft, Netherlands
[2] Erasmus MC Univ, Med Ctr, Dept Pathol, Josephine Nefkens Inst, Rotterdam, Netherlands
[3] Erasmus MC, Dept Publ Hlth, Ctr Clin Decis Sci, Rotterdam, Netherlands
[4] Erasmus MC Univ, Med Ctr, Dept Obstet & Gynecol, Rotterdam, Netherlands
关键词
cervical adenocarcinoma; immunohistochemistry; prognosis;
D O I
10.1002/ijc.22678
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the significance of prognostic markers-estrogen receptor, progesterone receptor, p53, MIB-1 and bcl-2 - in adenocarcinoma of the uterine cervix. In 101 patients with primary cervical adenocarcinoma, treated from 1989 to 2000, we evaluated clinical parameters in relation to these prognostic markers. Mean age of patients was 45 years. Seventy eight percent of the patients were in FIGO stage 1, 16% stage 11,7% stage III and IV. estrogen receptor, progesterone receptor, p53 and bcl-2 immunoreactivity was scored as 0 (up to 5% positive cells), 1+ (5-25% of cells positive), 2+ (26-50% of cells positive), 3+ (51-75% of cells positive) or 4+ (>76% of cells positive). MIB-1 was scored in 10 categories: 0-10,11-20,21-30,31-40,41-50,51-60,61-70,71-80,81-90,91- 100. The overall survival rate was 67%. Survival was not influenced by estrogen receptor, progesterone receptor, MIB-1, or bcl-2 strongly positive staining. Only p53 showed significant influence on survival, even when adjusted for stage or tumor grade. In conclusion, it does not seems useful to determine estrogen receptor, progesterone receptor, MIB-1 or bcl-2 in cervical adenocarcinomas as an indication of prognosis: survival is not influenced by presence or absence. However, if p53 staining is strongly positive survival is significantly worse than in tumors scored as negative or weak positive. (C) 2007 Wiley-Liss, Inc.
引用
收藏
页码:106 / 110
页数:5
相关论文
共 61 条
[1]   Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray [J].
Alkushi, A ;
Irving, J ;
Hsu, F ;
Dupuis, B ;
Liu, CL ;
Rijn, M ;
Gilks, CB .
VIRCHOWS ARCHIV, 2003, 442 (03) :271-277
[2]   Interpretation of p53 immunoreactivity in endometrial carcinoma: Establishing a clinically relevant cut-off level [J].
Alkushi, A ;
Lim, P ;
Coldman, A ;
Huntsman, D ;
Miller, D ;
Gilks, CB .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2004, 23 (02) :129-137
[3]   ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER [J].
ALLRED, DC ;
CLARK, GM ;
ELLEDGE, R ;
FUQUA, SAW ;
BROWN, RW ;
CHAMNESS, GC ;
OSBORNE, CK ;
MCGUIRE, WL .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) :200-206
[4]   Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma [J].
Cambruzzi, E ;
Zettler, CG ;
Alexandre, COP .
PATHOLOGY & ONCOLOGY RESEARCH, 2005, 11 (02) :114-120
[5]   Survival of patients with metastatic breast carcinoma - Importance of prognostic markers of the primary tumor [J].
Chang, J ;
Clark, GM ;
Allred, DC ;
Mohsin, S ;
Chamness, G ;
Elledge, RM .
CANCER, 2003, 97 (03) :545-553
[6]   Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan [J].
Chen, RJ ;
Lin, YH ;
Chen, CA ;
Huang, SC ;
Chow, SN ;
Hsieh, CY .
GYNECOLOGIC ONCOLOGY, 1999, 73 (02) :184-190
[7]   PROGESTERONE RECEPTORS AS A PROGNOSTIC FACTOR IN STAGE-II BREAST-CANCER [J].
CLARK, GM ;
MCGUIRE, WL ;
HUBAY, CA ;
PEARSON, OH ;
MARSHALL, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (22) :1343-1347
[8]   Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer [J].
Crawford, RAF ;
Caldwell, C ;
Iles, RK ;
Lowe, D ;
Shepherd, JH ;
Chard, T .
BRITISH JOURNAL OF CANCER, 1998, 78 (02) :210-214
[9]   The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions [J].
Dimitrakakis, C ;
Kymionis, G ;
Diakomanolis, E ;
Papaspyrou, I ;
Rodolakis, A ;
Arzimanoglou, I ;
Leandros, E ;
Michalas, S .
GYNECOLOGIC ONCOLOGY, 2000, 77 (01) :129-136
[10]   ADENOCARCINOMA AS AN INDEPENDENT RISK FACTOR FOR DISEASE RECURRENCE IN PATIENTS WITH STAGE IB CERVICAL-CARCINOMA [J].
EIFEL, PJ ;
BURKE, TW ;
MORRIS, M ;
SMITH, TL .
GYNECOLOGIC ONCOLOGY, 1995, 59 (01) :38-44